201 related articles for article (PubMed ID: 31469912)
1. Antinuclear antibodies are common and linked to poor response to omalizumab treatment in patients with CSU.
Ertaş R; Hawro T; Altrichter S; Özyurt K; Erol K; Ketenci Ertaş Ş; Maurer M
Allergy; 2020 Feb; 75(2):468-470. PubMed ID: 31469912
[No Abstract] [Full Text] [Related]
2. Hematologic parameters as biomarkers for antihistamine and omalizumab resistance in chronic spontaneous urticaria.
Magen E; Waitman DA; Kahan NR
Allergy Asthma Proc; 2021 Jan; 42(1):e17-e24. PubMed ID: 33404397
[No Abstract] [Full Text] [Related]
3. Use of omalizumab in uncontrolled chronic spontaneous urticaria also improved latex-induced contact urticaria.
Di Leo E; Calogiuri G; Macchia L; Nettis E
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):300-302. PubMed ID: 29802908
[No Abstract] [Full Text] [Related]
4. Addition of omalizumab to antihistamine treatment in chronic urticaria: A real-world study in China.
Chen YD; Maurer M; Yu M; Tu P; Zhao ZT
Ann Allergy Asthma Immunol; 2020 Aug; 125(2):217-219. PubMed ID: 32371240
[No Abstract] [Full Text] [Related]
5. Serum transglutaminase 2 activity as a potential biomarker of disease severity and response to omalizumab in chronic spontaneous urticaria.
Bae Y; Kang SH; Park JO; Park GH; Choi JH
Allergol Int; 2020 Apr; 69(2):304-306. PubMed ID: 31767272
[No Abstract] [Full Text] [Related]
6. A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real-world study in Belgium.
Lapeere H; Baeck M; Stockman A; Sabato V; Grosber M; Moutschen M; Lambert J; Vandebuerie L; de Montjoye L; Rabijns H; Allewaert K; Schrijvers R
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):127-134. PubMed ID: 31099916
[TBL] [Abstract][Full Text] [Related]
7. Omalizumab in the Treatment of Chronic Urticaria: The Effect of Drug Co-Administration and Co-Morbidities.
Tagka A; Lambrou GI; Nicolaidou E; Nakou E; Makris M; Stratigos A; Katsarou A
Antiinflamm Antiallergy Agents Med Chem; 2021; 20(1):39-50. PubMed ID: 32013838
[TBL] [Abstract][Full Text] [Related]
8. Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort study.
Salman A; Ergun T; Gimenez-Arnau AM
J Dermatolog Treat; 2020 Mar; 31(2):204-209. PubMed ID: 30821591
[No Abstract] [Full Text] [Related]
9. The use of omalizumab for treatment-refractory chronic spontaneous urticaria in a West Australian outpatient cohort.
Farrah G; Stevenson B; Lie K; Brusch A
Intern Med J; 2019 Apr; 49(4):526-528. PubMed ID: 30957371
[TBL] [Abstract][Full Text] [Related]
10. H1-Antihistamines May No Longer Be Necessary for Patients With Refractory Chronic Spontaneous Urticaria After Initiation of Omalizumab.
Ensina LF; Arruda LK; Campos RA; Criado RF; Rodrigues Valle S; Melo JM; Oliveira JC; Dortas JS; Cusato-Ensina AP; Camelo-Nunes IC; Agondi RC
J Investig Allergol Clin Immunol; 2020 Apr; 30(2):145-147. PubMed ID: 31762438
[No Abstract] [Full Text] [Related]
11. Use of Antihistamines During Omalizumab Therapy in Chronic Urticaria in the Routine Clinical Practice. A 48-Patient Observational Trial.
Menéndez-Sánchez M; Pérez-Fernández E; López-Estebaranz JL; Gómez-de la Fuente E
Actas Dermosifiliogr; 2024 Jun; 115(6):636-638. PubMed ID: 38382744
[No Abstract] [Full Text] [Related]
12. Baseline D-dimer plasma levels correlate with disease activity but not with the response to omalizumab in chronic spontaneous urticaria.
Asero R; Marzano AV; Ferrucci S; Genovese G; Cugno M
Allergy; 2019 Dec; 74(12):2538. PubMed ID: 31165493
[No Abstract] [Full Text] [Related]
13. Efficacy of omalizumab in chronic spontaneous urticaria associated with chronic inducible urticaria.
Dortas Junior S; Azizi G; Valle S
Ann Allergy Asthma Immunol; 2020 Oct; 125(4):486-487. PubMed ID: 32544531
[No Abstract] [Full Text] [Related]
14. Efficacy of drug therapies in antihistamine refractory chronic spontaneous urticaria: Real life data.
Unsel M
Asian Pac J Allergy Immunol; 2024 Jun; 42(2):138-146. PubMed ID: 33638629
[TBL] [Abstract][Full Text] [Related]
15. Chronic Spontaneous Urticaria: An Update on the Evaluation and Management.
Joshi SR; Anstey KM; Khan DA
Immunol Allergy Clin North Am; 2024 Aug; 44(3):503-515. PubMed ID: 38937012
[TBL] [Abstract][Full Text] [Related]
16. Dramatic improvement with colchicine in antihistamine- and omalizumab-resistant chronic spontaneous urticaria.
Abe N; Bohgaki M; Kasahara H
Clin Exp Dermatol; 2022 Dec; 47(12):2308-2310. PubMed ID: 36052842
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
Ghazanfar MN; Holm JG; Thomsen SF
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
[TBL] [Abstract][Full Text] [Related]
18. Differences between adult and pediatric chronic spontaneous urticaria from a cohort of 751 patients: Clinical features, associated conditions and indicators of treatment response.
Özçeker D; Can PK; Terzi Ö; Ornek SA; Değirmentepe EN; Kızıltac K; Sarac E; Kocatürk E
Pediatr Allergy Immunol; 2023 Feb; 34(2):e13925. PubMed ID: 36825740
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers predicting the controller dose of omalizumab in patients with chronic spontaneous urticaria.
Zubiaga-Fernandez L; Testera-Montes A; Rondon C; Perez-Sanchez N; Gomez-Perez F; Vega-Chicote JM; Bartra J; Ferrer M; Eguiluz-Gracia I; Torres MJ
Clin Exp Allergy; 2024 Jun; 54(6):402-411. PubMed ID: 38343206
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Omalizumab in Patients with Chronic Spontaneous Urticaria and Its Association with Serum IgE Levels and Eosinophil Count.
Tamer F; Gulru Erdogan F; Dincer Rota D; Yildirim D; Akpinar Kara Y
Acta Dermatovenerol Croat; 2019 Jun; 27(2):101-106. PubMed ID: 31351504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
